Clinical outcomes of newly diagnosed PCNSL treated with rituximab-methotrexate-cytarabine with or without ibrutinib: a retrospective study
RMA in combination with ibrutinib regimen improved response rates and survival in newly diagnosed PCNSL with no serious adverse effects. Mutations in <i>CARD11</i> gene may provide directions for patients to select targeted drugs.
Authors
- Lihua Qiu (ORCID: https://orcid.org/0000-0003-4637-1811)
- Huilai Zhang (ORCID: https://orcid.org/0000-0002-8558-3131)
- Yifei Sun (ORCID: https://orcid.org/0000-0002-5841-1262)
- Shiyong Zhou
- Lanfang Li (ORCID: https://orcid.org/0000-0001-7510-8751)
- Xianhuo Wang (ORCID: https://orcid.org/0000-0001-8742-4348)
- Zhengzi Qian (ORCID: https://orcid.org/0000-0002-2924-3212)
- Wei Li (ORCID: https://orcid.org/0000-0002-3960-1749)
- Wenhua Wang (ORCID: https://orcid.org/0000-0002-5429-728X)
- Zheng Song (ORCID: https://orcid.org/0000-0002-9495-4459)
- Bingyi Wang (ORCID: https://orcid.org/0009-0004-8834-893X)
Institutions
- Tianjin Medical University Cancer Institute and Hospital (CN)
- First Affiliated Hospital of Zhengzhou University (CN)
- Leukemia and Lymphoma Society (US)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-05-22
- DOI
- https://doi.org/10.3389/fimmu.2025.1579483
- Primary Topic
- CNS Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- BeiGene
- Tianjin Medical University
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences